Related Experiment Videos
Multimodality therapy for esophageal cancer.
1Division of Thoracic Surgery, University of Maryland Medical System, 22 South Greene Street, Room N4E35, Baltimore, MD 21202, USA.
The Surgical Clinics of North America
|December 11, 2002
Summary
Esophageal cancer incidence is rising, particularly in younger patients. Current evidence does not support routine preoperative chemotherapy for resectable esophageal cancer, but further research is needed to clarify treatment roles.
Area of Science:
- Oncology
- Epidemiology
- Surgical Oncology
Background:
- Esophageal cancer epidemiology is shifting, with increasing incidence in younger, healthier individuals.
- Current treatment strategies for resectable esophageal carcinoma lack strong evidence for routine preoperative chemotherapy.
Purpose of the Study:
- To review the current evidence regarding preoperative chemotherapy and chemoradiotherapy (CRT) for esophageal cancer.
- To highlight the need for further research, including large-scale randomized trials, to define optimal treatment protocols.
Main Methods:
- Review of published data on preoperative chemotherapy and CRT for esophageal cancer.
- Discussion of the role of neoadjuvant therapy, biologic markers, and advanced staging techniques.
Main Results:
- No strong evidence supports routine preoperative chemotherapy for surgically resectable esophageal cancer.
- The role of preoperative CRT is undetermined, requiring further clinical trials.
- Patients achieving a pathologically complete response (pCR) after neoadjuvant therapy show significant survival benefits.
Conclusions:
- Preoperative chemotherapy is not routinely recommended for resectable esophageal cancer.
- Further large-scale trials are essential to determine the efficacy of preoperative CRT and novel therapeutic approaches.
- Biologic markers and advanced staging (e.g., video-assisted thoracoscopy, laparoscopy) are crucial for personalized treatment and outcome evaluation.